Economical impact of preterm delivery management based on fetal fibronectin results;Impacto económico del manejo del parto pretérmino con base en el resultado de fibronectina fetal

Ginecologia y Obstetricia de Mexico

Volumn 72, Issue 8, 2004, Pages 385-393

  Alonso, L Ángel García ^a,b   Méndez, José Antonio Ayala ^a   Solís, Guillermo Jiménez ^a   Gutiérrez, Fabiola Aguilar ^a   Cueto, Laura Díaz ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Economical impact; Fetal fibronectin; Preterm labor

Indexed keywords

AMPICILLIN; CLINDAMYCIN; DEXAMETHASONE; ERYTHROMYCIN; FETAL FIBRONECTIN; FIBRONECTIN; INDOMETACIN; METRONIDAZOLE; ORCIPRENALINE; TERBUTALINE; UNCLASSIFIED DRUG; FFN PROTEIN, HUMAN; GLYCOPROTEIN;

ADULT; ARTICLE; CHILDBIRTH; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; FEMALE; GESTATIONAL AGE; HOSPITAL CARE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PREMATURE LABOR; RISK FACTOR; VAGINA SECRETION; BODY FLUID; CHEMISTRY; COMPARATIVE STUDY; ECONOMICS; PREGNANCY; PROSPECTIVE STUDY; UTERINE CERVIX;

BODY FLUIDS; CERVIX UTERI; COST-BENEFIT ANALYSIS; FEMALE; FIBRONECTINS; GLYCOPROTEINS; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 16644374294     PISSN: 03009041     EISSN: 03009041     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Seigal S, Rosembaum P, Stoskopf, et al. Comprehensive assessment of the health status of extremely low birth weight children at eight years of age: comparison with a reference group. J Pediatr 1994;125:411-7.
2. Lockwood CJ. Recent advances in elucidating the pathogenesis of preterm delivery, the detection of patients at risk and preventative therapies. Curr Opin Obstet Gynecol 1994;6:7.
3. McGregor J, French JI. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv 2000;55(5):1-19.
4. Leitich H, Egarter C, Kaider A, et al. Cervico vaginal fetal fibronectin as a marker for preterm delivery: a meta-analysis. Am J Obstet Gynecol 1999;180:1169-76.
5. Faron G. Prediction of preterm delivery with fetal fibronectin. A meta-analysis. Obstet Gynecol 1998;92(1):153-7.
6. Peaceman AM, Andrewa WW, Thorp JM, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997;177(1):13-18.
7. Joffe D, Burton B, Bernis-Heys R, et al. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999;180:581-6.
8. Giles WB. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000;182:439-42.
9. López RL, Francis JA, Garite TJ, Dubyak JM. Fetal fibronectin detection as a predictor of preterm birth in actual clinical practice. Am J Obstet Gynecol 2000;182(5):103-6.
10. García AA, Jiménez SG, Ayala MJA. Presencia de fibronectina fetal en secreción cervicovaginal como predictor de parto pretérmino. Ginecol Obstet Mex 1999;67:23-27.
11. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991;325:669-74.
12. Revah A, Hannah ME, Sue AK. Fetal fibronectin as a predictor of preterm birth: an overview. Am J Perinatol 1998;15(11):613-20.
13. García AA, Ayala MJA, Izquierdo PJC. Utilidad clínica de la expresión de fibronectina fetal en secreción cervicovaginal. Ginecol Obstet Mex 2002;70:379-84.
14. Bittar RE, Yamasaky AA, Sasaki S, Zugaib M. Fibronectin in patients at increased risk for preterm delivery. Am J Obstet Gynecol 1996;175(1):178-81.